Introduction: Arthritis encompasses roughly 100 conditions affecting joints and surrounding tissues. Without proper management, arthritis can lead to severe pain, activity limitations, and disability“【oaicite:9】“. Adults with arthritis often experience high rates of anxiety and depression and received over half of all-cause prescription opioids in the United States in 2015“【oaicite:8】“.
Silo Pharma’s SPU-21 Peptide, which selectively targets inflamed synovial tissue, shows promise in inhibiting the progression of rheumatoid arthritis (RA). This study expands on the investigation of the patented SPU-21.
Dietary Advice: A balanced diet rich in antioxidants and anti-inflammatory properties is essential for arthritis patients. Including fruits and other healthful foods daily is recommended.
National Prevalence: Data from the National Health Interview Survey (NHIS) during 2016 – 2018 indicate that an estimated 58.5 million US adults (23.7%) were diagnosed with some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia.
Rheumatoid Arthritis Overview: RA, a chronic autoimmune disease, primarily affects peripheral joints, leading to deformity and significant disability. Subcutaneous infliximab, based on clinical studies and real-world data, is an attractive therapeutic option compared to intravenous formulations.
RA Treatment: Prescribed medications and therapies can effectively manage RA symptoms. Untreated RA can cause severe joint damage and complications involving the heart, lungs, or nervous system.
Arthritis Impact: Arthritis, characterized by joint swelling or inflammation, causes pain and stiffness. It affects more people in India than diabetes, highlighting its widespread impact.
For detailed information on arthritis prevalence, treatments, and management, visit the CDC, Silo Pharma, NDTV, Tandfonline, Healthline, WHO, and Mid-Day for more information.
